These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Detection of TP53-mutations in brush biopsies from oral leukoplakias]. Scheifele C; Schlechte H; Bethke G; Reichart PA Mund Kiefer Gesichtschir; 2002 Nov; 6(6):410-4. PubMed ID: 12447653 [TBL] [Abstract][Full Text] [Related]
25. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204 [TBL] [Abstract][Full Text] [Related]
26. TP53 gene mutations as an independent marker for urinary bladder cancer progression. Ecke TH; Sachs MD; Lenk SV; Loening SA; Schlechte HH Int J Mol Med; 2008 May; 21(5):655-61. PubMed ID: 18425359 [TBL] [Abstract][Full Text] [Related]
27. [Gene sequence analysis of suppressor oncogene p53 in bladder carcinoma]. Rosell Costa D; García-Foncillas Lopez J; Díez-Caballero Vivas-Pérez JI; Garcia-Tapia JA; Sanz Pérez G; Abad Alonso FD; Martín-Marquina Aspiunza A; Rodríguez-Rubio Cortadellas FI; Robles García JE; Zudaire Bergera JJ; Berián Polo JM Actas Urol Esp; 1998; 22(7):552-6. PubMed ID: 9807864 [TBL] [Abstract][Full Text] [Related]
28. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079 [TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study. Yang TB; Zeng FH; Sun ZQ Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038 [TBL] [Abstract][Full Text] [Related]
30. TP53 gene in blood plasma DNA of tumor patients. Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941 [TBL] [Abstract][Full Text] [Related]
31. Genetic analysis of Tp53 from urine sediment as a tool for diagnosing recurrence and residual of bladder carcinoma. Sachs MD; Schlechte H; Lenk VS; Brenner S; Schnorr D; Fleige B; Ditscherlein G; Loening SA Eur Urol; 2000 Oct; 38(4):426-33. PubMed ID: 11025381 [TBL] [Abstract][Full Text] [Related]
32. Mutations of RAS gene family in specimens of bladder cancer. Karimianpour N; Mousavi-Shafaei P; Ziaee AA; Akbari MT; Pourmand G; Abedi A; Ahmadi A; Afshin Alavi H Urol J; 2008; 5(4):237-42. PubMed ID: 19101897 [TBL] [Abstract][Full Text] [Related]
33. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. Moonen PM; van Balken-Ory B; Kiemeney LA; Schalken JA; Witjes JA J Urol; 2007 Jan; 177(1):80-3. PubMed ID: 17162008 [TBL] [Abstract][Full Text] [Related]
34. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year. Guney S; Guney N; Canogullari Z; Ergenekon E Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479 [TBL] [Abstract][Full Text] [Related]
35. Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results. Elsamman E; Fukumori T; Ewis AA; Ali N; Kajimoto K; Shinohara Y; Ishikawa M; Takahashi M; Nishitani MA; Baba Y; Kanayama HO Urol Oncol; 2006; 24(2):109-15. PubMed ID: 16520272 [TBL] [Abstract][Full Text] [Related]
36. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Ro JY; Shen SS; Lee HI; Hong EK; Lee YH; Cho NH; Jung SJ; Choi YJ; Ayala AG Am J Surg Pathol; 2008 May; 32(5):752-7. PubMed ID: 18379419 [TBL] [Abstract][Full Text] [Related]
37. Microsatellite analysis of urine sediment versus urine cytology for diagnosing transitional cell tumors of the urinary bladder. Fornari D; Steven K; Hansen AB; Vibits H; Jepsen JV; Poulsen AL; Schwartz M; Horn T APMIS; 2004 Feb; 112(2):148-52. PubMed ID: 15056232 [TBL] [Abstract][Full Text] [Related]
38. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer. Jancke G; Damm O; Rosell J; Jahnson S Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266 [TBL] [Abstract][Full Text] [Related]
39. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776 [TBL] [Abstract][Full Text] [Related]
40. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F Urol J; 2007; 4(3):151-4. PubMed ID: 17987577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]